A humanized anti-CD47 monoclonal antibody (mAb), which directly inhibits the CD47−SIRPα interaction, is currently in clinical trials21 and shows a strong activity against GBM in multiple murine models18. The gene discussed is CD47; the disease is glioblastoma.